Meeting
2013 Breast Cancer Symposium
Correlation of molecular alterations with efficacy of everolimus in hormone-receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2.
Authors
Hope S. Rugo
University of California, San Francisco, San Francisco, CA
Hope S. Rugo , Gabriel N. Hortobagyi , Martine J. Piccart-Gebhart , Howard A. Burris III, Mario Campone , Shinzaburo Noguchi , Alejandra T. Perez , Ines Deleu , Mikhail Shtivelband , Louise Provencher , Norikazu Masuda , Shaker R. Dakhil , Ian Anderson , David Chen , Amy Damask , Alan Huang , Robert McDonald , Tanya Taran , Tarek Sahmoud , Jose Baselga
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
General Session
Session Title
General Session X: Updates on Treatment of Metastatic Disease and Sequencing in Various Subsets of Patients
Track
Systemic Therapy
Sub Track
Advanced Disease
Clinical Trial Registration Number
NCT00863655
Citation
J Clin Oncol 31, 2013 (suppl 26; abstr 142)
DOI
10.1200/jco.2013.31.26_suppl.142
Abstract #
142
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Molecular alterations associated with rapid progression following CDK4/6 inhibitors (CDKi) in metastatic hormone receptor–positive breast cancer (mHRBC).
First Author: Malinda T West
Poster
2017 Genitourinary Cancers Symposium
Dissecting the genomic landscape of metastatic bladder cancer using circulating tumor DNA.
First Author: Werner J. Struss
First Author: Fabricio Racca
Poster
2023 ASCO Annual Meeting
Real-world (RW) outcomes of patients (pts) with advanced breast cancer (aBC) with and without resistance alterations (alts) detected in cell-free circulating tumor DNA (ctDNA) prior to CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) treatment.
First Author: Seth Andrew Wander